SCHEMBL4838463

SCHEMBL4838463

COc1ccc2c(C3CCCC3)nnc(Cl)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.39
ACHE P22303 5/20 0.37
BCHE P06276 4/20 0.37
CHRM1 P11229 1/20 0.37
GRIN1 Q05586 3/20 0.36
GRIN2A Q12879 3/20 0.36
PDE10A Q9Y233 1/20 0.36
DYRK1A Q13627 2/20 0.35
CYP17A1 P05093 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
CACNA2D1 P54289 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834726 0.94 PDE10A (0.40) MPIACHEBCHECHRM1GRIN1
SCHEMBL4124640 0.88 PARP14 (0.39) PDE10APDE4APDE4BPDE4CPDE4D
SCHEMBL4118008 0.80 BRD4 (0.51) ACHE
SCHEMBL2305992 0.73 SMN1; SMN2 (0.46) ACHEBCHEDYRK1ACYP17A1CYP11B1
SCHEMBL8556734 0.73 MEN1 (0.49) ALDH1A1LMNAHPGD
SCHEMBL30014669 0.73 SMN1; SMN2 (0.46) ACHEBCHEDYRK1ACYP17A1CYP11B1
SCHEMBL4838830 0.73 PDE4A (0.41) PDE4APDE4BPDE4CPDE4D
SCHEMBL4843527 0.72 DYRK1A (0.45) MPIDYRK1APTGDR2PDE4BLMNA
SCHEMBL2306186 0.70 SMN1; SMN2 (0.42) ACHEBCHEDYRK1ACYP17A1CYP11B1
SCHEMBL4124808 0.70 PDE4A (0.45) DYRK1APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 MPI 1803/4885ACHE 1785/4885BCHE 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.